Bicycle Therapeutics (NASDAQ:BCYC) Rating Increased to Sell at Wall Street Zen

by · The Markets Daily

Wall Street Zen upgraded shares of Bicycle Therapeutics (NASDAQ:BCYC – Free Report) from a strong sell rating to a sell rating in a research note issued to investors on Saturday.

Several other research firms have also recently weighed in on BCYC. Needham & Company LLC cut their price objective on Bicycle Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Citigroup restated a “market outperform” rating on shares of Bicycle Therapeutics in a research note on Wednesday, June 3rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bicycle Therapeutics in a report on Wednesday, July 8th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $12.00 price target on shares of Bicycle Therapeutics in a research report on Thursday, April 30th. Five investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $13.86.

View Our Latest Stock Report on Bicycle Therapeutics

Bicycle Therapeutics Price Performance

Shares of BCYC opened at $3.90 on Friday. The company has a market capitalization of $272.96 million, a PE ratio of -1.43 and a beta of 1.55. Bicycle Therapeutics has a one year low of $3.74 and a one year high of $9.16. The company’s fifty day moving average price is $4.10 and its 200 day moving average price is $4.74.

Bicycle Therapeutics (NASDAQ:BCYC – Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.14). The firm had revenue of $0.63 million for the quarter, compared to the consensus estimate of $4.22 million. Bicycle Therapeutics had a negative net margin of 311.11% and a negative return on equity of 33.22%. Analysts anticipate that Bicycle Therapeutics will post -2.23 earnings per share for the current year.

Insider Transactions at Bicycle Therapeutics

In other Bicycle Therapeutics news, CEO Kevin Lee sold 5,905 shares of the business’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $4.27, for a total value of $25,214.35. Following the sale, the chief executive officer owned 605,408 shares of the company’s stock, valued at $2,585,092.16. The trade was a 0.97% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 9,977 shares of company stock valued at $42,702. Insiders own 22.00% of the company’s stock.

Hedge Funds Weigh In On Bicycle Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Portland Investment Counsel Inc. bought a new stake in Bicycle Therapeutics in the second quarter valued at about $64,000. Marquette Asset Management LLC acquired a new position in Bicycle Therapeutics in the second quarter worth about $309,000. FNY Investment Advisers LLC lifted its stake in Bicycle Therapeutics by 247.4% during the second quarter. FNY Investment Advisers LLC now owns 26,250 shares of the company’s stock worth $111,000 after purchasing an additional 18,693 shares during the period. GAMMA Investing LLC lifted its stake in Bicycle Therapeutics by 512.9% during the second quarter. GAMMA Investing LLC now owns 7,704 shares of the company’s stock worth $33,000 after purchasing an additional 6,447 shares during the period. Finally, Flax Pond Capital LLC boosted its holdings in Bicycle Therapeutics by 1.4% during the first quarter. Flax Pond Capital LLC now owns 176,136 shares of the company’s stock valued at $817,000 after purchasing an additional 2,503 shares in the last quarter. 86.15% of the stock is owned by institutional investors.

Bicycle Therapeutics Company Profile

(Get Free Report)

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.

Featured Stories